Dabigatran versus enoxaparin for prevention of venous thromboembolism after hip or knee arthroplasty: A pooled analysis of three trials
Authors:
- R.J. FriedmanRFR.J. Friedman
- O.E. DahlODO.E. Dahl
- N. RosencherNRN. Rosencher
- J.A. CapriniJCJ.A. Caprini
- A.A. KurthAKA.A. Kurth
- C.W. FrancisCFC.W. Francis
- A. ClemensACA. Clemens
- S. HantelSHS. Hantel
- J.M. SchneeJSJ.M. Schnee
- B.I. ErikssonBEB.I. Eriksson
- 1 September 2010
- journal article
- research article
- Published by Elsevier in Thrombosis Research
- Vol. 126 (3) , 175-182
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Economic evaluation of dabigatran etexilate for the prevention of venous thromboembolism after total knee and hip replacement surgeryClinical Therapeutics, 2009
- Clinical Pharmacokinetics and Pharmacodynamics of the Oral Direct Thrombin??Inhibitor Dabigatran EtexilateClinical Pharmacokinetics, 2008
- Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE‐MODEL randomized trialJournal of Thrombosis and Haemostasis, 2007
- Insufficient duration of venous thromboembolism prophylaxis after total hip or knee replacement when compared with the time course of thromboembolic eventsThe Journal of Bone and Joint Surgery. British volume, 2007
- A Once-Daily, Oral, Direct Factor Xa Inhibitor, Rivaroxaban (BAY 59-7939), for Thromboprophylaxis After Total Hip ReplacementCirculation, 2006
- BAY 59-7939: an oral, direct Factor Xa inhibitor for the prevention of venous thromboembolism in patients after total knee replacement. A phase II dose-ranging studyJournal of Thrombosis and Haemostasis, 2005
- A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trialJournal of Thrombosis and Haemostasis, 2005
- Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO IJournal of Thrombosis and Haemostasis, 2004
- The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS studyJournal of Thrombosis and Haemostasis, 2003
- Measuring inconsistency in meta-analysesBMJ, 2003